<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02392468</url>
  </required_header>
  <id_info>
    <org_study_id>1289.27</org_study_id>
    <nct_id>NCT02392468</nct_id>
  </id_info>
  <brief_title>Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers</brief_title>
  <official_title>Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Single site, parallel-group, double-blind trial of low or high dose of BI 409306 to evaluate
      the ocular and systemic safety and pharmacokinetics during 14 day treatment period in
      patients with schizophrenia, Alzheimer's disease, or age comparable healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2015</start_date>
  <completion_date type="Actual">August 10, 2017</completion_date>
  <primary_completion_date type="Actual">August 10, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of subjects with Adverse Events (AE), coded to the Medical Dictionary for Regulatory Activities, System Organ Class Eye disorders, as determined by the investigator at End of Study</measure>
    <time_frame>up to 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with drug-related AEs as determined by the investigator at End of Study</measure>
    <time_frame>up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss - maximum measured concentration of the analyte in plasma at steady-state</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,ss - time from dosing to maximum measured concentration of the analyte in plasma at steady-state.</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>BI 409306 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose of BI 409306</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 409306 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose of BI 409306</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306 matching placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>BI 409306 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306 matching placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>BI 409306 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>low dose</description>
    <arm_group_label>BI 409306 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 409306</intervention_name>
    <description>high dose</description>
    <arm_group_label>BI 409306 high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Schizophrenia group:

               -  Patients with established diagnoses of schizophrenia (per Diagnostic and
                  Statistic Manual of Mental Disorder, version V) with the all of the following
                  clinical features:

                    -  Clinically stable and are in the residual (non-acute) phase of their illness
                       for at least 8 weeks prior to randomisation

                    -  Current antipsychotic and concomitant psychotropic medications must meet the
                       criteria below:

                         -  Maintained on current atypical (second generation) antipsychotic
                            medications (in any approved dosage form) other than Clozapine and on
                            current dose for at least 8 weeks prior to randomisation, and/or

                         -  Maintained on current typical (first generation) antipsychotic
                            medications and on current dose for at least 6 months, optionally
                            combined with anticholinergics if treated with a stable dose for at
                            least 6 months prior to randomisation, and/or

                         -  Maintained on current concomitant psychotropic medications other than
                            anticholinergics, antiepileptics and lithium, and on current dose for
                            at least 8 weeks prior to randomisation. Antiepileptics and lithium are
                            allowed if initiated at least 6 months prior to randomisation.

                    -  Have no more than a moderate severity rating on hallucinations and delusions
                       (Positive and Negative Syndrome Scale (PANSS), positive syndrome
                       Hallucinatory Behavior item score &lt;= 4 and Delusions item score &lt;= 4)

                    -  Have no more than a moderate severity rating on positive formal thought
                       disorder (PANSS, positive syndrome Conceptual Disorganization item score &lt;=
                       4)

                    -  Have a minimal level of extrapyramidal symptoms (Simpson-Angus Scale total
                       score &lt; 6) and depressive symptoms (PANSS, general psychopathology syndrome
                       Depression item score &lt;= 4)

               -  Male or female patients age 18 to 55 years.

          -  Alzheimer's Disease group:

               -  Patients with diagnosis of mild Alzheimer's Dementia based on DSM-V and in
                  accordance with the recommendations from the National Institute on
                  Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's
                  disease.

               -  Mini-Mental State Examination (MMSE) score of 18-26.

               -  Male or female patients age 55 to 85 years, who have not been taking acetyl
                  cholinesterase inhibitors (donepezil, galantamine, rivastigmine) and/or memantine
                  for at least 3 months or on stable dose of acetyl cholinesterase inhibitors
                  (donepezil, galantamine, rivastigmine) and/or memantine at least 3 months before
                  randomization.Patients older than 85 years may be included based on an acceptable
                  general health status, (e.g. concomitant diseases, physical capability to follow
                  the required study procedures [visits etc.]) per investigators judgement.

               -  Availability of a pre-existing cranial computer tomography (CCT) or magnetic
                  resonance imaging (MRI) scan of the brain (initiation of radiological imaging is
                  not required) not older than one year prior to screening; if not available, a CCT
                  must be performed at screening. Results of radiological brain imaging must be
                  compatible with Diagnosis of Alzheimer's Disease and exclusion of relevant signs
                  indicative of potential vascular dementia (see also exclusion criteria).

               -  If needed, a caregiver may be present during site activities.

          -  Age-comparable male or female healthy volunteers age 18 to 85 years. Healthy
             volunteers older than 85 years may be included based on an acceptable general health
             status, (e.g. concomitant diseases, physical capability to follow the required study
             procedures [visits etc.]) per investigators judgement:

               -  After 10 patients with schizophrenia (as described above) are entered into the
                  study, the median age of the group will be computed. Five healthy volunteers at
                  or below the median age but greater than 18 years old and five healthy volunteers
                  above the median but less than 55 will be entered into the study.

               -  Similarly, after 10 patients with AD are entered, the median age will be
                  computed. Five healthy volunteers at or below the median age but greater than 55
                  years old and five healthy volunteers above the median but less than 85 will be
                  entered into the study.

          -  Subjects must exhibit reliability and physiologic capability to comply with all
             protocol procedures.

          -  Signed and dated written informed consent by date of Visit 1 in accordance with Good
             Clinical Practice and the local legislation. If the patient needs a legal
             representative, then this legal representative must give written informed consent as
             well.

        Exclusion criteria:

          -  Presence of active ocular conditions with or without visual impairment due to any
             causes (e.g. cataract, chorioretinal macular lesion, amblyopia, active diabetic
             retinopathy, uncontrolled glaucoma, active inflammation or infection, etc.) in one eye
             or both eyes at the screening phase.

          -  Planned ocular treatment (e.g. intravitreal antivascular growth factor,
             corticosteroids) or surgery during the study period.

          -  Current or planned use of ocular or systemic corticosteroids.

          -  Current or planned use of medications known to be toxic to the retina, lens, optic
             nerve

          -  Subjects treated with more than two antipsychotic medications (including more than two
             dosage forms).

          -  Dementia in Alzheimers Disease patients, secondary to other disorders (based on
             clinical data and/or current laboratory findings and/or on a pre-existing cranial MRI
             or CCT).

          -  Neurological disease (other than Dementia of Alzheimer Type such as: Lewy body
             dementia - primary diagnosis, Huntington's disease, Parkinson's Disease encephalitis,
             epilepsy, vascular or multi-infarct dementia, stroke, congenital mental deficiency, or
             multiple sclerosis), or mental retardation.

          -  Subjects needing to take long-acting hypnotics or anxiolytic (i.e. Diazepam).

          -  For AD patients, the following drugs are prohibited for 3 months prior to
             randomization and for the duration of the trial:

               -  tricyclic antidepressants,

               -  antidepressants that are monoamine oxidase inhibitors,

               -  neuroleptics with moderate or greater anticholinergic potency (e.g.,
                  chlorpromazine, fluphenazine, loxapine, perphenazine, thioridazine),

               -  anticholinergic medications.

               -  Intake of St. John's wort, Carbamazepine and extracts from Ginko as they are
                  relevant CYP2C19 inducers.

          -  Substantial concomitant cerebrovascular disease (defined by a history of a
             stroke/intracranial haemorrhagia temporally related to the onset of worsening of
             cognitive impairment).

          -  Any suicidal ideation of type 4 or 5 in the Columbia Suicidal Severity Rating Scale
             (C-SSRS) in the past 3 months.

          -  Any suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt,
             aborted attempt, or preparatory acts or behavior).

          -  History or diagnosis of symptomatic and unstable/uncontrolled gastrointestinal,
             hepatic, renal, respiratory, cardiovascular, metabolic, immunological, haematological
             or hormonal disorders.

          -  For female subjects:

             --Pre-menopausal women (last menstruation &lt;=1 year prior to informed consent) who:

               -  are nursing or pregnant or

               -  are of child-bearing potential and are not practicing an acceptable method of
                  birth control

          -  For male subjects: Men who are able to father a child, unwilling to be abstinent or
             use adequate contraception.

          -  Known history, or new diagnosis of HIV infection.

          -  Significant renal disease (CLCR &lt; 30 mL/min).

          -  Bodyweight &lt; 50 kg.

          -  Indication of liver disease.

          -  History of neurologic (e.g. stroke, seizure without a clear and resolved etiology,
             concussion accompanying loss of consciousness) or psychiatric condition.

          -  History of malignancy within the last 5 years, except for basal cell carcinoma.

          -  Planned elective surgery requiring general anaesthesia, or hospitalisation during the
             study period.

          -  Significant history of drug dependence

          -  Clinically significant uncompensated hearing loss. Use of hearing aids is not allowed.

          -  Further exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altman Clinical and Translational Research Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memory Enhancement Center of America, Inc.</name>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

